Yichang Renfu Medicine

Renfu Pharmaceutical Group Co., Ltd. was established in 1993 and listed on the Shanghai Stock Exchange in 1997. It is a leading enterprise in the pharmaceutical industry in Hubei Province, one of the top 30 pharmaceutical companies in China, a national technological innovation demonstration enterprise, and a leading enterprise in the internationalization of preparations among Chinese pharmaceutical companies. It has established a leading or leading position in many domestic subdivisions such as narcotic drugs, steroid hormone drugs, and Uyghur ethnic medicine. In 2022, the company achieved operating income of 22.338 billion yuan, a year-on-year increase of 8.71%; net profit attributable to the parent company was 2.484 billion yuan, a year-on-year increase of 88.60%; in the first half of 2023, the company achieved operating income of 12.383 billion yuan, a year-on-year increase of 17.06%; Net profit was 1.324 billion yuan.
The company focuses on the pharmaceutical industry and supplements on the pharmaceutical business, and steadily promotes internationalization. The pharmaceutical industry has realized the production capacity of all dosage forms in the entire industry chain of pharmaceutical intermediates-APIs-pharmaceutical excipients-pharmaceutical preparations; the pharmaceutical business adheres to the positioning of comprehensive medical service provider, lays out business networks, and achieves full regional coverage; internationalization has formed a With global pharmaceutical full value chain capabilities in R&D, registration, production and sales, more than 80 products have been exported to more than 70 countries and regions around the world.
The company focuses on innovative drugs, innovative preparations and high-end generic drugs with high clinical value, aims at cutting-edge fields, and builds a first-class innovative R&D industrialization platform. It has established R&D centers in Wuhan, Yichang, China, New Jersey, St. Louis and other places in the United States, gathering more than 1,700 medical R&D personnel, including more than 190 Ph.D.s and 7 experts enjoying special allowances from the State Council. The group has more than 350 research projects, including more than 30 Class I new drugs, 24 projects have been listed as major national new drug creation projects, and 794 authorized patents have been granted.
Humanwell Pharmaceuticals adheres to the development strategy of being a leader in the pharmaceutical market segment and gradually realizes the leap from an international follower to a leader through the three strategic paths of focus, innovation and internationalization, creating a globally competitive company. A world-class pharmaceutical company.

Related Products

Share:

More Application
Get Free Quote
Scroll to Top